Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2011-05-24
2011-05-24
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S085200, C514S021200
Reexamination Certificate
active
07947265
ABSTRACT:
A fusion protein comprising GM-CSF and IL-15 is described. The fusion protein has unexpected immune suppressive properties and is useful in a variety of therapeutic applications.
REFERENCES:
patent: WO03/035105 (2003-05-01), None
Rafei et al (2007) Blood, vol. 109, No. 5, pp. 2234-2242.
Dranoff G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences. 90: 3539-43 (1993).
Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. Journal of Immunology. 156: 238-45 (1996).
Gillies, Stephen et al. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunology Immunotherapy. 51: 449-460 (2002).
Stagg J., Wu JH, Bougamin N., Galipeau J. Granulocyte-macrophage colony stimulating factor and interleukin-2 fusion cDNA for cancer gene therapy. Cancer Research. 64: 8795-99 (2004).
Waldmann TA, Tagaya Y. The multifaced regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annual Reviews in Immunology. 17: 19-49 (1999).
Tagaya Y., Bamford RN, DeFilippis AP, Waldmann TA. IL15: a pleotropic cytokine with diverse receptor/signalling pathways whose expression in controlled at multiple levels. Immunity. 4: 329-36 (1996).
Fehniger TA, Caliguiri MA. Interleukin 15: biology and relevance to human diseases. Blood. 97: 14-32 (2001).
Mrozek E., Anderson P, Caliguiri MA. Role of interleukin-15 in the development of CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 87: 2632-40 (1996).
Ohteki T., et al. The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T-cell receptor-alpha/beta+ (NK1+T) cells, natural killer cells, and intestinal intraepithelial T cells. Journal of Experimental Medicine. 187: 967-72 (1998).
Fehniger TA et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. Journal of Immunology. 162: 4511-20 (1999).
Atedzoe BN, Ahmand A., Menezes J. Enhancement of natural killer cell cytotoxicity by the human herpes-7 via IL-15 induction.Journal of Immunology. 159: 4966-72 (1997).
Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin-15 promotes angiogenesis in vivo.Biochemical Biophysical Research Communication. 233: 231-7 (1997).
Estess P, Nandi A, Mohamadzadeh M, Siegelman MH. Interleukin 15 induces endothelial hyaluronan expression in vitro and promotes activated T cell extravasation through a CD44-dependent pathway in vivo.Journal of Experimental Medicine. 190: 9-19 (1999).
Kisselva T., Bhattacharya S., Braunstein J., Schindler CW. Signalling through the JAK/STAT pathway, recent advances and future challenges.Gene. 285: 1-24 (2002).
Bromberg J., Darnell JE. The role of STATs in transcriptional control and their impact on cellular function.Oncogene. 19: 2468-73 (2000).
Smithgall TE et al. Control of myeloid differentiation and survival by Stats.Oncogene. 19: 2612-2618 (2000).
Catlett-Falcone R. et al. Constitutive activation of STAT3 signalling confers resistance to apoptosis in human U266 myeloma cells.Immunity. 10: 105-15 (1999).
Niu G. et al. Roles of activated Src and STAT3 signalling in melanoma tumor cell growth.Oncogene. 21: 7001-10 (2002).
Wang T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signalling in tumor cells.Nature Medicine. 10: 48-54 (2003).
Kortylwski M et al. Inhibiting Stat3 signalling in the hematopoietic system elicits multicomponent antitumor immunity.Nature Medicine. 11: 1314-21 (2005).
Lorenzen I, Dingley AJ, Jacques Y, Grotzinger J. The Structure of the Interleukin-15α Receptor and Its Implications for Ligand Binding.Journal of Biological Chemistry. 281: 6642-6647 (2006).
Jérôme Bernard, et al. Identification of an Interleukin-15α Receptor-binding Site on Human Interleukin-15.Journal of Biological Chemistry. 279: 24313-22, (2004).
Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signalling complex: Paradigm for a heterotrimeric cytokine receptor.Proceeding National Academy of Science. 103: 2788-2793 (2006).
Sainathan SK et al. PEGylated murine Granulocyte-macrophage colony-stimulating factor: production, purification, and characterization.Protein Expression&Purification. 44: 94-103 (2005).
Burgess AW, Metcalf D. Serum half-life and organ distribution of radiolabeled colony stimulating factor in mice.Experimental Hematology. 5: 456-64 (1977).
Pettit DK, et al. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling.Journal of Biological Chemistry. 272: 2312-8 (1997).
Mosmman TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells.Advances in Immunology. 46: 111-47 (1989).
Ulett GC, Ketheesan N, Hirst RG. Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BI/6 mice during infection with virulentBurkholderia pseudomallei. Infection and Immunity. 68: 2034-42 (2000).
Wahl S.M., Wen J., Moutsopoulos NM (2006). The kiss of death: interrupted by NK-cell close encounters of another kind.Trends in Immunology. 4: 161-4 (2006).
Perri SR, et al. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression.Cancer Research. 65: 8359-65 (2005).
Hoontrakoon, R. et al. “Interleukin-15 Inhibits Spontaneous Apoptosis in Human Eosinophils via Autocrine Production of Granulocyte Macrophage-Colony Stimulating Factor and Nuclear Factor-kB Activation”, Am. J. Respir. Cell Mol. Biol. 2002, vol. 26, p. 404-412. ISSN 1044-1549.
Raza, K. et al. “Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis”. Arthritis Research & Therapy. Jul. 2006, vol. 8, No. 4, R120. ISSN 1478-6362.
Valdembri, D. et al. “In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF”. FASEB J. Feb. 2002, vol. 16, No. 2, p. 225-7. ISSN 1530-6860.
Galipeau Jacques
Rafei Moutih
Bereskin & Parr LLP / S.E.N.C.R.L., s.r.l.
Gravelle Micheline
McGill University
Mertz Prema
LandOfFree
Fusion proteins and methods for modulation of immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion proteins and methods for modulation of immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion proteins and methods for modulation of immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678092